A registry of people with pancreatic cancer (OSPREY)

Cancer type:

Pancreatic cancer

Status:

Open

Phase:

Other

This is a registry to collect information about a device called OncoSil.

It is open to people:

with locally advanced pancreatic cancer who are having or are about to be treated with chemotherapy that includes gemcitabine
whose doctor has offered treatment with the OncoSil device

More about this trial

Doctors can treat pancreatic cancer with chemotherapy. Gemcitabine is one chemotherapy drug they can use. You can have it either by itself or with other chemotherapy drugs.

OncoSil is a type of brachytherapy device. The OncoSil device consists of tiny radioactive Open a glossary item particles suspended in a gel like substance. The doctor injects the OncoSil device directly into the cancer inside your body. The radiation only goes to the cancer cells and doesn’t affect the surrounding tissue.

Doctors already use OncoSil in addition to chemotherapy that includes gemcitabine to treat pancreatic cancer. But it isn’t widely available.

The aim of the registry is to collect information about the OncoSil device and assess how well it works with chemotherapy.

Who can enter

The following bullet points are a summary of the entry conditions for this registry. Talk to your doctor or the team if you are unsure about any of these. They will be able to advise you.

Who can take part

You may be able to join this registry if all of the following apply. You:

have pancreatic cancer that has spread into the nearby tissue (locally advanced) and cannot have surgery to remove it
are having the OncoSil device in a hospital taking part
are fit and well enough. Your doctor will assess this.
are having gemcitabine chemotherapy or you are to start chemotherapy that includes gemcitabine

Who can’t take part

You cannot join this registry if any of these apply. You:

had OncoSil as part of a clinical trial
are taking part in another clinical trial

Trial design

This is an international registry. The team need 500 people in the EU and the UK who are treated with the OncoSil device for pancreatic cancer in addition to chemotherapy that includes gemcitabine.

You are having chemotherapy that includes gemcitabine or are about to start chemotherapy that includes gemcitabine for your pancreatic cancer.

You have the OncoSil device put in place during a week in the cycle of treatment Open a glossary item when you aren’t having chemotherapy. The procedure will take about 30 minutes but you may need to stay overnight if your doctor thinks it appropriate. Before you leave hospital you may have a Bremsstrahlung scan. This is a special type of scan like an x-ray. It is to make sure the radioactive microparticles are in the correct place and position. At the same time you may also have a CT scan.

After you have the OncoSil device put in your chemotherapy schedule will continue as planned.

The study team look at your medical records to collect information about the treatment effect, any side effects and further cancer treatment.

Hospital visits

The registry itself does not require any additional hospital visits. However before treatment with the OncoSil device, you might have a CT scan 1 or 2 weeks before having the device put in. Your doctor will let you know if this applies to you.

Side effects

Joining the registry itself doesn’t have any risks as it will only collect data from your medical records.

The OncoSil device uses radiation to treat cancer cells. Like any other medical treatment OncoSil may cause side effects.

Previous studies found that the OncoSil device did have some side effects. But they were usually mild or rare. You might have some of these side effects. These included: